Free Trial
NASDAQ:MOLN

Molecular Partners Q3 2023 Earnings Report

Molecular Partners logo
$3.90 -0.15 (-3.58%)
As of 11:28 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Molecular Partners EPS Results

Actual EPS
-$0.40
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Molecular Partners Revenue Results

Actual Revenue
$2.88 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Molecular Partners Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Thursday, October 26, 2023
Conference Call Time
7:00AM ET

Earnings Documents

Molecular Partners Earnings Headlines

Q2 Earnings Estimate for MOLN Issued By Leerink Partnrs
Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.
See More Molecular Partners Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Molecular Partners? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Molecular Partners and other key companies, straight to your email.

About Molecular Partners

Molecular Partners (NASDAQ:MOLN), a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

View Molecular Partners Profile

More Earnings Resources from MarketBeat